Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced (ELECLA)
Study Details
Study Description
Brief Summary
Effectiveness analysis of neoadjuvant chemotherapy in the treatment of locally advanced colon cancer. ELECLA trial
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Participants in this study selected patients according to homogeneous inclusion criteria and will be treated either with a uniform protocol of neoadjuvant chemotherapy, surgery and complementary chemotherapy (intervention group), or with the standard scheme of postoperative surgery and chemotherapy (control group ). All patients will be studied basally through clinical examinations and radiological and endoscopic tests usually used to reach the diagnosis of Locally Advanced Colon Cancer . In the group of patients receiving neoadjuvant treatment, the CT scan will be repeated after the completion of preoperative chemotherapy to restage the disease and quantify the degree of tumor response.
Finally, the project tries to determine whether the neoadjuvant treatment scheme increases disease-free survival (SLE) at 2 and 5 years and overall survival (OS) at 5 years. Likewise, the toxicity derived from chemotherapy treatment and perioperative morbidity and mortality will be analyzed to evaluate the feasibility and safety of the therapeutic procedure. The rate of completion of chemotherapy in both groups will also be compared.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention Group 3 cycles XELOX + Surgery+ 5 cycles XELOX |
Combination Product: CAPECITABINE AND OXALIPLATIN
Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
|
| Other: Control group Surgery + 8 cycles XELOX |
Combination Product: CAPECITABINE AND OXALIPLATIN
Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
|
Outcome Measures
Primary Outcome Measures
- Disease-free survival (SLE) at 2 years [From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.]
To determine whether the proposed treatment with neoadjuvant chemotherapy, surgery and complementary chemotherapy increases the disease-free survival (SLE) at 2 years postoperatively, compared with standard treatment, surgery and complementary chemotherapy.
Secondary Outcome Measures
- To assess whether neoadjuvant chemotherapy, surgery and complementary chemotherapy increases SLE 5 years postoperatively, compared to standard treatment of surgery and complementary chemotherapy [From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.]
From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.
- To evaluate whether neoadjuvant chemotherapy, surgery and complementary chemotherapy increase OS at 2 and 5 years postoperatively, in comparison with standard treatment of surgery and complementary chemotherapy. [From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.]
From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.
- To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment [From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.]
From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.
Eligibility Criteria
Criteria
Inclusion Criteria:
- CLINICS
-
Histological confirmation of colon adenocarcinoma.
-
Patients of both sexes with age over 18 years.
-
Good general condition of the patient (Karnofsky> 60% or ECOG (Eastern Cooperative Oncology Group) <2).
-
Analytical at the time of inclusion with figures of Hemoglobin> 10 g / dL; Leukocytes> 3.0 109 / L, Platelets> 100,000, Glomerular Filtration> 50 ml / min and Total Bilirubin <25 micromol / l.
-
Absence of contraindication for chemotherapy.
-
Acceptance and signature of the Informed Consent.
- OF IMAGE
-
Radiological signs, evaluated by CT, of T4 or T3 tumor infiltration> 5 mm of transmural invasion.
-
With or without lymph node involvement by CT.
-
No metastatic involvement in other organs (M0).
-
Radiologically resectable disease. REFERENCES TO THE TREATMENT
-
That they will undergo elective surgery with curative intent (R0).
Exclusion Criteria:
-
- Important comorbidity, uncontrolled angina or a history of acute myocardial infarction in the last 6 months.
-
Personal history of another malignancy in the last 5 years, with the exception of melanoma.
-
Uncontrolled infection 4. Pregnancy or lactation. 5. Peripheral neuropathy> grade
-
- Rectum cancer (<15 cm of the anal margin or below peritoneal reflection). 7. Presence of distant metastasis or peritoneal carcinomatosis. 8. Intestinal obstruction. 9. Existence of microsatellite instability 10. Refusal to participate or to give written consent 11. Impossibility, at the investigator's discretion, to understand the purpose of the study or to comply with its procedures.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Complejo Asistencial Universitario de Leon | León | Spain | 24071 |
Sponsors and Collaborators
- Universidad de León
Investigators
- Principal Investigator: JORGE ARREDONDO, DR., COMPLEJO ASISTENCIAL UNIVERSITARIO DE LEON
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- Nº AEMPS: 16-0553
- 2016-002970-10